Current Status and Future Perspectives of Liquid Biopsy in Non-small Cell Lung Cancer

Overview

Journal J Pathol Transl Med

Specialty Biomedical Engineering

Date 2020 May 29

PMID 32460474

Citations 11

Authors

Sunhee Chang

Jae Young Hur

Yoon-La Choi

Chang Hun Lee

Wan Seop Kim

Affiliations

Soon will be listed here.

Abstract

With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practice in advanced NSCLC patients to guide tyrosine kinase inhibitor treatment. In the near future, liquid biopsy will be a crucial prognostic, predictive, and diagnostic method in NSCLC. Here we present the current status and future perspectives of liquid biopsy in NSCLC.

Citing Articles

Comparison of tissue-based and plasma-based testing for EGFR mutation in non-small cell lung cancer patients.

Kang Y, Shin D, Park J, Hwang C, Lee H, Lee J J Pathol Transl Med. 2025; 59(1):60-67.

PMID: 39815744 PMC: 11736281. DOI: 10.4132/jptm.2024.10.01.

Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer.

Bararia A, Chakraborty P, Roy P, Chattopadhay B, Das A, Chatterjee A World J Gastroenterol. 2023; 29(15):2241-2260.

PMID: 37124888 PMC: 10134423. DOI: 10.3748/wjg.v29.i15.2241.

Exosomal MicroRNA Analyses in Esophageal Squamous Cell Carcinoma Cell Lines.

Kim S, Kim G, Park S, Hwa Kwon C, I H, Lee M J Clin Med. 2022; 11(15).

PMID: 35956043 PMC: 9369365. DOI: 10.3390/jcm11154426.

Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics.

Lee Y, Na K, Woo H, Kim H Diagnostics (Basel). 2022; 12(5).

PMID: 35626258 PMC: 9139381. DOI: 10.3390/diagnostics12051102.

Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics.

Koh H, Park E, Kim H Diagnostics (Basel). 2022; 12(2).

PMID: 35204416 PMC: 8871294. DOI: 10.3390/diagnostics12020326.

References

Lee J, Hur J, Kim I, Kim H, Choi C, Lee J . Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA. BMC Cancer. 2018; 18(1):1236. PMC: 6288853. DOI: 10.1186/s12885-018-5138-3. View

Gandara D, Paul S, Kowanetz M, Schleifman E, Zou W, Li Y . Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018; 24(9):1441-1448. DOI: 10.1038/s41591-018-0134-3. View

Quan P, Sauzade M, Brouzes E . dPCR: A Technology Review. Sensors (Basel). 2018; 18(4). PMC: 5948698. DOI: 10.3390/s18041271. View

Abbosh C, Birkbak N, Wilson G, Jamal-Hanjani M, Constantin T, Salari R . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017; 545(7655):446-451. PMC: 5812436. DOI: 10.1038/nature22364. View

Siravegna G, Marsoni S, Siena S, Bardelli A . Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9):531-548. DOI: 10.1038/nrclinonc.2017.14. View

Kawahara A, Fukumitsu C, Azuma K, Taira T, Abe H, Takase Y . A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients. Cytopathology. 2018; 29(2):150-155. DOI: 10.1111/cyt.12517. View

Heitzer E, Auer M, Hoffmann E, Pichler M, Gasch C, Ulz P . Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013; 133(2):346-56. PMC: 3708119. DOI: 10.1002/ijc.28030. View

Keppens C, Dequeker E, Patton S, Normanno N, Fenizia F, Butler R . International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA. BMC Cancer. 2018; 18(1):804. PMC: 6085634. DOI: 10.1186/s12885-018-4694-x. View

Sholl L, Aisner D, Allen T, Beasley M, Cagle P, Capelozzi V . Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med. 2016; 140(8):825-9. DOI: 10.5858/arpa.2016-0163-SA. View

10.

Sorensen B, Wu L, Wei W, Tsai J, Weber B, Nexo E . Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014; 120(24):3896-901. PMC: 4303984. DOI: 10.1002/cncr.28964. View

11.

Lo Y, Chan K, Sun H, Chen E, Jiang P, Lun F . Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010; 2(61):61ra91. DOI: 10.1126/scitranslmed.3001720. View

12.

Cheung A, Chow C, To K . Latest development of liquid biopsy. J Thorac Dis. 2018; 10(Suppl 14):S1645-S1651. PMC: 6035915. DOI: 10.21037/jtd.2018.04.68. View

13.

Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J . Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. 2014; 14:294. PMC: 4014134. DOI: 10.1186/1471-2407-14-294. View

14.

Lo Y, Zhang J, Leung T, Lau T, Chang A, Hjelm N . Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999; 64(1):218-24. PMC: 1377720. DOI: 10.1086/302205. View

15.

Jenkins S, Yang J, Ramalingam S, Yu K, Patel S, Weston S . Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 12(7):1061-1070. DOI: 10.1016/j.jtho.2017.04.003. View

16.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

17.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

18.

Wang W, Kong P, Ma G, Li L, Zhu J, Xia T . Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. Oncotarget. 2017; 8(26):43180-43191. PMC: 5522137. DOI: 10.18632/oncotarget.17858. View

19.

Tong Y, Zhao Z, Liu B, Bao A, Zheng H, Gu J . 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2018; 37(1):68. PMC: 5870746. DOI: 10.1186/s13046-018-0735-1. View

20.

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil P, Van Meerbeeck J, Lardon F . Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2016; 107:100-107. DOI: 10.1016/j.lungcan.2016.04.026. View